Health experts have described the introduction of Lenacapavir (LEN), an injectable pre-exposure prophylaxis (PrEP), as a major breakthrough in Malawi’s efforts to prevent new HIV infections.
In an interview on Tuesday, sexual and reproductive medicine specialist Dr. Zaziwe Gundah said LEN’s introduction presents a significant step forward in HIV prevention because it offers a more convenient alternative to existing prevention methods.
He said that the drug is particularly beneficial for key populations such as sex workers, men who have sex with men, discordant couples and others whose occupations or behaviours place them at risk of HIV infection.
“The significance of Lenacapavir lies in its ability to improve adherence to HIV prevention because it is administered once every six months, unlike daily oral PrEP,” said Gundah.
He said the biannual injectable also provides privacy for users while reducing the burden of taking medication every day.
Said Gundah: “Compared to the two-month Cabotegravir injection, Lenacapavir offers longer-lasting protection and has demonstrated exceptional effectiveness during clinical trials.
“Together with the current antiretroviral therapy programmes, this drug has the potential to help Malawi achieve zero HIV transmission within the coming years.”
In a press release on Friday, Ministry of Health and Sanitation Principal Secretary for Administration Bestone Chisamile announced the introduction of Lenacapavir.
The ministry said the six-month injectable PrEP will be introduced in public health facilities effective July 1 as an additional HIV prevention option to strengthen the country’s HIV prevention programme and accelerate progress towards ending Aids as a public health threat by 2030.
